ALK and non-small cell lung carcinoma: Several novel therapeutic approaches targeting ALK-positive NSCLC are currently under evaluation in clinical trials, including second-generation ALK inhibitors, such as LDK378, CH5424802 (RO5424802), and AP26113, and new agents shock protein 90 inhibitors.